CDK2 and breast cancer: We show that although the proliferation of luminal breast cancers is initially CDK4/6-dependent, CDK2 activity can overcome persistent CDK4/6 inhibition, eventually restoring Rb phosphorylation to a level that facilitates cellular entry into S-phase.